R A Marrie1, J D Fisk2, K J Stadnyk3, H Tremlett4, C Wolfson5, S Warren6, V Bhan7, B N Yu1. 1. Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada. 2. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; Capital District Health Authority, Halifax, Canada. 3. Capital District Health Authority, Halifax, Canada. 4. Department of Medicine (Neurology), University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Epidemiology and Biostatistics and Occupational Health, McGill University, Montréal, Quebec, Canada; Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada. 6. Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada. 7. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada; Capital District Health Authority, Halifax, Canada.
Abstract
INTRODUCTION: As the population ages and the prevalence of comorbid conditions increases, the need for feasible, validated methods of comorbidity surveillance in chronic diseases such as multiple sclerosis (MS) increases. METHODS: Using kappa (k) statistics, we evaluated the performance of administrative case definitions for comorbidities commonly observed in MS by comparing agreement between Manitoba (MB) administrative data and self-report (n = 606) and Nova Scotia (NS) administrative data and self-report (n = 1923). RESULTS: Agreement between the administrative definitions and self-report was substantial for hypertension (k = 0.69 [NS], 0.76 [MB]) and diabetes (k = 0.70 [NS], 0.66 [MB]); moderate for hyperlipidemia (k = 0.53 [NS], 0.51 [MB]) and heart disease (k = 0.42 [NS], 0.51 [MB]) and fair for anxiety (k = 0.27 [NS], 0.26 [MB]). In NS, agreement was substantial for inflammatory bowel disease (k = 0.71) and moderate for epilepsy (k = 0.48). CONCLUSION: Administrative definitions for commonly observed comorbidities in MS performed well in 2 distinct jurisdictions. This suggests that they could be used more broadly across Canada and in national studies.
INTRODUCTION: As the population ages and the prevalence of comorbid conditions increases, the need for feasible, validated methods of comorbidity surveillance in chronic diseases such as multiple sclerosis (MS) increases. METHODS: Using kappa (k) statistics, we evaluated the performance of administrative case definitions for comorbidities commonly observed in MS by comparing agreement between Manitoba (MB) administrative data and self-report (n = 606) and Nova Scotia (NS) administrative data and self-report (n = 1923). RESULTS: Agreement between the administrative definitions and self-report was substantial for hypertension (k = 0.69 [NS], 0.76 [MB]) and diabetes (k = 0.70 [NS], 0.66 [MB]); moderate for hyperlipidemia (k = 0.53 [NS], 0.51 [MB]) and heart disease (k = 0.42 [NS], 0.51 [MB]) and fair for anxiety (k = 0.27 [NS], 0.26 [MB]). In NS, agreement was substantial for inflammatory bowel disease (k = 0.71) and moderate for epilepsy (k = 0.48). CONCLUSION: Administrative definitions for commonly observed comorbidities in MS performed well in 2 distinct jurisdictions. This suggests that they could be used more broadly across Canada and in national studies.
Authors: Ruth Ann Marrie; Scott B Patten; Lindsay I Berrigan; Helen Tremlett; Christina Wolfson; Sharon Warren; Stella Leung; Kirsten M Fiest; Kyla A McKay; John D Fisk Journal: Int J MS Care Date: 2018 Mar-Apr
Authors: Ruth Ann Marrie; John Fisk; Helen Tremlett; Christina Wolfson; Sharon Warren; James Blanchard; Scott B Patten Journal: Neurol Clin Pract Date: 2016-04
Authors: Ruth Ann Marrie; Scott B Patten; Helen Tremlett; Christina Wolfson; Sharon Warren; Lawrence W Svenson; Nathalie Jette; John Fisk Journal: Neurology Date: 2016-03-09 Impact factor: 9.910
Authors: Ruth Ann Marrie; John D Fisk; Helen Tremlett; Christina Wolfson; Sharon Warren; Aruni Tennakoon; Stella Leung; Scott B Patten Journal: Neurology Date: 2015-10-30 Impact factor: 9.910